title: Comparative analysis of oestrogen and raloxifene effects on the phospholipid composition of high density lipoproteins in healthy postmenopausal women.
abstract: The beneficial effect of selective oestrogen receptor modulators such as raloxifene in cardiovascular disease may be mediated partly by favourable changes in the phospholipid composition of high density lipoprotein (HDL) subclasses. In Group A (oestrogen alone) HDL2 phosphatidylcholine increased (P<0.001), while there was a decrease in HDL2 phosphatidylinositol (P<0.05) and HDL2 phosphatidylethanolamine (P<0.05) compared to controls (baseline). In the same group, HDL3 phosphatidylcholine increased (P<0.001) and HDL3 phosphatidylethanolamine decreased (P<0.01). In Group B (raloxifene) HDL2 phosphatidylcholine increased (P<0.001) as well as HDL2 diphosphatidylglycerol (P<0.01) while there were decreases in HDL2 sphingomyelin (P<0.01) and HDL2 phosphatidylethanolamine (P<0.05). In the same group, an increase in HDL3 phosphatidylcholine (P<0.001) and a reduction in HDL3 phosphatidylinositol (P<0.05) were observed as well as a decrease in HDL3 phosphatidylethanolamine (P<0.01) and HDL3 diphosphatidylglycerol (P<0.05). The significance of these results is discussed.
authors.affiliation: Department of Biological Chemistry, University of Athens, School of Medicine, Athens, Greece.
authors.forename: C
authors.initials: C
authors.lastname: Piperi
authors.forename: C
authors.initials: C
authors.lastname: Kalofoutis
authors.forename: A
authors.initials: A
authors.lastname: Papapanagiotou
authors.forename: C
authors.initials: C
authors.lastname: Skenderi
authors.forename: A
authors.initials: A
authors.lastname: Kalofoutis
mesh_terms: D000367:Age Factors; D000368:Aged; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006115:Greece; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood* / Q000187:drug effects*; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects / Q000502:physiology; D011336:Probability; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage*; D012016:Reference Values; D018570:Risk Assessment; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D004967:Estrogens; D008075:Lipoproteins, HDL; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride